Using a recent patient case from my practice, I describe how I am incorporating new selective RET inhibitors such as selpercatinib into managing patients with RET fusion–positive NSCLC.
My take on how selective RET inhibitors are changing the standard of care in advanced thyroid cancer.
Here are my thoughts on what patients need to know about biomarker testing and targeted therapies for lung and thyroid cancers.
Read expert answers to key questions asked by healthcare professionals during a series of live webinars focused on the optimal use of selective RET inhibitors in the treatment of advanced cancers with RET alterations, including how to differentiate between these agents and what to do after progression on them.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.